Serif Biomedicines has emerged from stealth mode to continue developing “modified DNA,” a new class of therapeutics designed ...

Lipid nanoparticles address key drug delivery challenges, including immune evasion, toxicity, and regulatory approval.

Please note: We ask that people only attend one Listening Session, as space is limited, so that we can hear as many voices as possible.

Lipid nanoparticles (LNPs) have emerged as a transformative platform in the field of neurotherapeutics, particularly for targeting the aging brain.